View ValuationFaes Farma 将来の成長Future 基準チェック /26Faes Farma利益と収益がそれぞれ年間9.7%と7.9%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に13.1% 7.8%なると予測されています。主要情報9.7%収益成長率7.81%EPS成長率Pharmaceuticals 収益成長11.8%収益成長率7.9%将来の株主資本利益率13.10%アナリストカバレッジLow最終更新日08 Dec 2025今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jul 08Faes Farma, S.A. to Report First Half, 2026 Results on Jul 30, 2026Faes Farma, S.A. announced that they will report first half, 2026 results on Jul 30, 2026お知らせ • May 07Faes Farma, S.A., Annual General Meeting, Jun 24, 2026Faes Farma, S.A., Annual General Meeting, Jun 24, 2026. Location: palacio euskalduna, avenida abandoibarra 4, bilbao., Spainお知らせ • Feb 03Faes Farma, S.A. to Report Fiscal Year 2025 Results on Feb 26, 2026Faes Farma, S.A. announced that they will report fiscal year 2025 results on Feb 26, 2026お知らせ • Nov 06Faes Farma, S.A. to Report Nine Months, 2025 Results on Nov 04, 2025Faes Farma, S.A. announced that they will report nine months, 2025 results on Nov 04, 2025お知らせ • Jul 22Faes Farma, S.A. to Report First Half, 2025 Results on Jul 24, 2025Faes Farma, S.A. announced that they will report first half, 2025 results on Jul 24, 2025お知らせ • Jun 11Faes Farma, S.A. (BME:FAE) has signed a purchase agreement to acquire Sifi S.P.A. from 21 Investimenti III Fund managed by 21 Invest Sgr S.p.A. and others for €350 million.Faes Farma, S.A. (BME:FAE) has signed a purchase agreement to acquire Sifi S.P.A. from 21 Investimenti III Fund managed by 21 Invest Sgr S.p.A. and others for €350 million on June 10, 2025. Faes Farma, S.A. will pay an earnout/contingent payment of €80.5 million cash. The transaction values Sifi S.P.A. at €270 million upfront Enterprise Value plus earn outs related to Akantior linked to certain sales levels in Europe that exceed forecasts. The maximum total amount of the earn-outs would be €50.5 million spread over six milestones/payments until 2041. In addition, there is a potential payment of €30 million conditional on the commercial launch of Akantior in the US plus one digit to low two-digit tiered payments on US net sales following until the expiration of the patent in the US, or US loss of exclusivity. Sifi S.P.A. acquisition expected to be EPS accretive from year one, even before commercial and cost synergies. Faes Farma, S.A. has secured committed debt financing from J.P. Morgan SE to fund the acquisition. The transaction is expected to close in the third quarter of 2025, subject to approval by competition and foreign investment authorities in the various countries and Faes Farma, S.A.'s extraordinary shareholders' meeting, which will be convened in the coming days. J.P. Morgan SE acted as financial advisor for Faes Farma, S.A. Cuatrecasas, Gonçalves Pereira, S.L.P. acted as legal advisor for Faes Farma, S.A. Chiomenti Studio Legale acted as legal advisor for Faes Farma, S.A. Ernst & Young Transaction Advisory Services España acted as due diligence provider for Faes Farma, S.A. Gide Loyrette Nouel A.A.R.P.I. acted as due diligence provider for Faes Farma, S.A. Wolf Theiss Rechtsanwalte GmbH & Co Kg acted as due diligence provider for Faes Farma, S.A. At Kearney Sa acted as due diligence provider for Faes Farma, S.A. Evercore Partners International LLP acted as financial advisor for 21 Invest Sgr S.p.A. Mediobanca Banca di Credito Finanziario S.p.A. acted as financial advisor for 21 Invest Sgr S.p.A. Hogan Lovells Studio Legale acted as legal advisor for 21 Invest Sgr S.p.A.お知らせ • May 20Faes Farma, S.A., Annual General Meeting, Jun 24, 2025Faes Farma, S.A., Annual General Meeting, Jun 24, 2025. Location: palacio euskalduna, avenida abandoibarra, n 4, de bilbao., Spainお知らせ • Apr 09Faes Farma, S.A. to Report Q1, 2025 Results on Apr 30, 2025Faes Farma, S.A. announced that they will report Q1, 2025 results on Apr 30, 2025お知らせ • Mar 26Faes Farma, S.A. (BME:FAE) agreed to acquire Laboratorios Edol Productos Farmacêuticos, S.A.Faes Farma, S.A. (BME:FAE) agreed to acquire Laboratorios Edol Productos Farmacêuticos, S.A. on March 25, 2025. Laboratorios Edol Productos Farmacêuticos has reported sales of exceeding €30 million in 2024. The closing of the transaction is subject to the satisfactory completion of conditions precedent, including the submission of audited annual accounts for 2024 and the continuation of some of the existing commercial agreements with Laboratorios Edol.お知らせ • Feb 13Faes Farma, S.A. to Report Fiscal Year 2024 Results on Feb 28, 2025Faes Farma, S.A. announced that they will report fiscal year 2024 results at 12:00 PM, Romance Standard Time on Feb 28, 2025お知らせ • Feb 09Faes Farma, S.A. to Report Fiscal Year 2023 Results on Feb 27, 2024Faes Farma, S.A. announced that they will report fiscal year 2023 results on Feb 27, 2024お知らせ • Feb 08Faes Farma, S.A., Annual General Meeting, Jun 15, 2024Faes Farma, S.A., Annual General Meeting, Jun 15, 2024.Board Change • Jun 29Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Jun 12Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.New Risk • Jun 08New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.2% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 0.2% per year for the foreseeable future. Minor Risk Dividend is not well covered by cash flows (184% cash payout ratio).Board Change • May 11Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • May 05Faes Farma, S.A. (BME:FAE) completed the acquisition of NovoSci.Faes Farma, S.A. (BME:FAE) agreed to acquire NovoSci on January 12, 2023. Faes Farma received authorization for the acquisition. Mariano Ucar, Ariadna Casanueva and Soraya Romero of Cuatrecasas acted as legal advisors to Faes Farma in the transaction.Faes Farma, S.A. (BME:FAE) completed the acquisition of NovoSci on May 3, 2023.Reported Earnings • May 03First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: €130.1m (up 4.0% from 1Q 2022). Net income: €27.6m (up 3.7% from 1Q 2022). Profit margin: 21% (in line with 1Q 2022). Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.Board Change • Apr 21Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Mar 29Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Mar 02Full year 2022 earnings releasedFull year 2022 results: Revenue: €461.7m (up 7.7% from FY 2021). Net income: €89.6m (up 7.7% from FY 2021). Profit margin: 19% (in line with FY 2021). Revenue is forecast to stay flat during the next 3 years compared to a 6.5% growth forecast for the Pharmaceuticals industry in the United Kingdom.Board Change • Feb 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Jan 11Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Nov 22Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Nov 04Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: €106.0m (down 5.2% from 3Q 2021). Net income: €21.1m (down 11% from 3Q 2021). Profit margin: 20% (down from 21% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.5% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.Board Change • Oct 26Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Oct 05Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Aug 26Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Jul 30Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €120.9m (up 16% from 2Q 2021). Net income: €26.3m (up 2.3% from 2Q 2021). Profit margin: 22% (down from 25% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to decline by 4.9% while the industry in the United Kingdom is not expected to grow.Board Change • Jul 11Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Jun 08Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 07Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 1 experienced director. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Mar 14Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Jan 25Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Aug 26Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 1 experienced director. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Jul 29Second quarter 2021 earnings releasedThe company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: €104.1m (up 4.4% from 2Q 2020). Net income: €25.7m (up 3.9% from 2Q 2020). Profit margin: 25% (in line with 2Q 2020). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Board Change • Jul 29Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 1 experienced director. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • May 04First quarter 2021 earnings releasedThe company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: €104.9m (down 14% from 1Q 2020). Net income: €21.5m (up 3.1% from 1Q 2020). Profit margin: 21% (up from 17% in 1Q 2020). The increase in margin was driven by lower expenses.Upcoming Dividend • Dec 09Upcoming Dividend of €0.14 Per ShareWill be paid on the 23rd of December to those who are registered shareholders by the 16th of December. The trailing yield of 0.7% is below the top quartile of British dividend payers (4.8%), and is lower than industry peers (3.7%).Is New 90 Day High Low • Dec 03New 90-day high: €3.83The company is up 17% from its price of €3.29 on 04 September 2020. The British market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €3.50 per share.業績と収益の成長予測BATS-CHIXE:FAEE - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202772710997N/A312/31/20266679384N/A312/31/202557169-103N/A39/30/2025571105N/AN/AN/A6/30/202554410573101N/A3/31/2025524109N/AN/AN/A12/31/202451011176115N/A9/30/202450498N/AN/AN/A6/30/20244949744106N/A3/31/202448295N/AN/AN/A12/31/202347392-1101N/A9/30/202347290N/AN/AN/A6/30/202346990-998N/A3/31/202346791N/AN/AN/A12/31/20224628926107N/A9/30/202246086N/AN/AN/A6/30/20224668850113N/A3/31/202244988N/AN/AN/A12/31/2021429822080N/A9/30/202141681N/AN/AN/A6/30/202139874856N/A3/31/202139473N/AN/AN/A12/31/2020411735378N/A9/30/202040877N/AN/AN/A6/30/2020407735778N/A3/31/202040968N/AN/AN/A12/31/2019383644668N/A9/30/201937960N/AN/AN/A6/30/201936359N/A74N/A3/31/201935154N/AN/AN/A12/31/201834052N/A59N/A9/30/201833451N/AN/AN/A6/30/201833049N/A58N/A3/31/201830847N/AN/AN/A12/31/201728241N/A42N/A9/30/201726639N/AN/AN/A6/30/201725039N/A43N/A3/31/201724138N/AN/AN/A12/31/201623737N/A50N/A9/30/201622635N/AN/AN/A6/30/201622234N/A40N/A3/31/201622032N/AN/AN/A12/31/201521430N/A41N/A9/30/201520728N/AN/AN/A6/30/201520327N/A42N/A3/31/201519626N/AN/AN/A12/31/201419825N/A32N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: FAEEの予測収益成長率 (年間9.7% ) は 貯蓄率 ( 3% ) を上回っています。収益対市場: FAEEの収益 ( 9.7% ) UK市場 ( 11.4% ) よりも低い成長が予測されています。高成長収益: FAEEの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: FAEEの収益 ( 7.9% ) UK市場 ( 4% ) よりも速いペースで成長すると予測されています。高い収益成長: FAEEの収益 ( 7.9% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: FAEEの 自己資本利益率 は、3年後には低くなると予測されています ( 13.1 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/12/15 02:47終値2025/09/17 00:00収益2025/09/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Faes Farma, S.A. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Javier Esteban LarioBanco de Sabadell. S.A.Jesús Gómez DominguezBanco SantanderJosé Romero HerreroBanco Santander6 その他のアナリストを表示
お知らせ • Jul 08Faes Farma, S.A. to Report First Half, 2026 Results on Jul 30, 2026Faes Farma, S.A. announced that they will report first half, 2026 results on Jul 30, 2026
お知らせ • May 07Faes Farma, S.A., Annual General Meeting, Jun 24, 2026Faes Farma, S.A., Annual General Meeting, Jun 24, 2026. Location: palacio euskalduna, avenida abandoibarra 4, bilbao., Spain
お知らせ • Feb 03Faes Farma, S.A. to Report Fiscal Year 2025 Results on Feb 26, 2026Faes Farma, S.A. announced that they will report fiscal year 2025 results on Feb 26, 2026
お知らせ • Nov 06Faes Farma, S.A. to Report Nine Months, 2025 Results on Nov 04, 2025Faes Farma, S.A. announced that they will report nine months, 2025 results on Nov 04, 2025
お知らせ • Jul 22Faes Farma, S.A. to Report First Half, 2025 Results on Jul 24, 2025Faes Farma, S.A. announced that they will report first half, 2025 results on Jul 24, 2025
お知らせ • Jun 11Faes Farma, S.A. (BME:FAE) has signed a purchase agreement to acquire Sifi S.P.A. from 21 Investimenti III Fund managed by 21 Invest Sgr S.p.A. and others for €350 million.Faes Farma, S.A. (BME:FAE) has signed a purchase agreement to acquire Sifi S.P.A. from 21 Investimenti III Fund managed by 21 Invest Sgr S.p.A. and others for €350 million on June 10, 2025. Faes Farma, S.A. will pay an earnout/contingent payment of €80.5 million cash. The transaction values Sifi S.P.A. at €270 million upfront Enterprise Value plus earn outs related to Akantior linked to certain sales levels in Europe that exceed forecasts. The maximum total amount of the earn-outs would be €50.5 million spread over six milestones/payments until 2041. In addition, there is a potential payment of €30 million conditional on the commercial launch of Akantior in the US plus one digit to low two-digit tiered payments on US net sales following until the expiration of the patent in the US, or US loss of exclusivity. Sifi S.P.A. acquisition expected to be EPS accretive from year one, even before commercial and cost synergies. Faes Farma, S.A. has secured committed debt financing from J.P. Morgan SE to fund the acquisition. The transaction is expected to close in the third quarter of 2025, subject to approval by competition and foreign investment authorities in the various countries and Faes Farma, S.A.'s extraordinary shareholders' meeting, which will be convened in the coming days. J.P. Morgan SE acted as financial advisor for Faes Farma, S.A. Cuatrecasas, Gonçalves Pereira, S.L.P. acted as legal advisor for Faes Farma, S.A. Chiomenti Studio Legale acted as legal advisor for Faes Farma, S.A. Ernst & Young Transaction Advisory Services España acted as due diligence provider for Faes Farma, S.A. Gide Loyrette Nouel A.A.R.P.I. acted as due diligence provider for Faes Farma, S.A. Wolf Theiss Rechtsanwalte GmbH & Co Kg acted as due diligence provider for Faes Farma, S.A. At Kearney Sa acted as due diligence provider for Faes Farma, S.A. Evercore Partners International LLP acted as financial advisor for 21 Invest Sgr S.p.A. Mediobanca Banca di Credito Finanziario S.p.A. acted as financial advisor for 21 Invest Sgr S.p.A. Hogan Lovells Studio Legale acted as legal advisor for 21 Invest Sgr S.p.A.
お知らせ • May 20Faes Farma, S.A., Annual General Meeting, Jun 24, 2025Faes Farma, S.A., Annual General Meeting, Jun 24, 2025. Location: palacio euskalduna, avenida abandoibarra, n 4, de bilbao., Spain
お知らせ • Apr 09Faes Farma, S.A. to Report Q1, 2025 Results on Apr 30, 2025Faes Farma, S.A. announced that they will report Q1, 2025 results on Apr 30, 2025
お知らせ • Mar 26Faes Farma, S.A. (BME:FAE) agreed to acquire Laboratorios Edol Productos Farmacêuticos, S.A.Faes Farma, S.A. (BME:FAE) agreed to acquire Laboratorios Edol Productos Farmacêuticos, S.A. on March 25, 2025. Laboratorios Edol Productos Farmacêuticos has reported sales of exceeding €30 million in 2024. The closing of the transaction is subject to the satisfactory completion of conditions precedent, including the submission of audited annual accounts for 2024 and the continuation of some of the existing commercial agreements with Laboratorios Edol.
お知らせ • Feb 13Faes Farma, S.A. to Report Fiscal Year 2024 Results on Feb 28, 2025Faes Farma, S.A. announced that they will report fiscal year 2024 results at 12:00 PM, Romance Standard Time on Feb 28, 2025
お知らせ • Feb 09Faes Farma, S.A. to Report Fiscal Year 2023 Results on Feb 27, 2024Faes Farma, S.A. announced that they will report fiscal year 2023 results on Feb 27, 2024
お知らせ • Feb 08Faes Farma, S.A., Annual General Meeting, Jun 15, 2024Faes Farma, S.A., Annual General Meeting, Jun 15, 2024.
Board Change • Jun 29Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Jun 12Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
New Risk • Jun 08New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.2% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 0.2% per year for the foreseeable future. Minor Risk Dividend is not well covered by cash flows (184% cash payout ratio).
Board Change • May 11Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • May 05Faes Farma, S.A. (BME:FAE) completed the acquisition of NovoSci.Faes Farma, S.A. (BME:FAE) agreed to acquire NovoSci on January 12, 2023. Faes Farma received authorization for the acquisition. Mariano Ucar, Ariadna Casanueva and Soraya Romero of Cuatrecasas acted as legal advisors to Faes Farma in the transaction.Faes Farma, S.A. (BME:FAE) completed the acquisition of NovoSci on May 3, 2023.
Reported Earnings • May 03First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: €130.1m (up 4.0% from 1Q 2022). Net income: €27.6m (up 3.7% from 1Q 2022). Profit margin: 21% (in line with 1Q 2022). Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
Board Change • Apr 21Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Mar 29Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Mar 02Full year 2022 earnings releasedFull year 2022 results: Revenue: €461.7m (up 7.7% from FY 2021). Net income: €89.6m (up 7.7% from FY 2021). Profit margin: 19% (in line with FY 2021). Revenue is forecast to stay flat during the next 3 years compared to a 6.5% growth forecast for the Pharmaceuticals industry in the United Kingdom.
Board Change • Feb 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Jan 11Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Nov 22Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Nov 04Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: €106.0m (down 5.2% from 3Q 2021). Net income: €21.1m (down 11% from 3Q 2021). Profit margin: 20% (down from 21% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.5% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
Board Change • Oct 26Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Oct 05Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Aug 26Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Jul 30Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €120.9m (up 16% from 2Q 2021). Net income: €26.3m (up 2.3% from 2Q 2021). Profit margin: 22% (down from 25% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to decline by 4.9% while the industry in the United Kingdom is not expected to grow.
Board Change • Jul 11Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Jun 08Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 07Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 1 experienced director. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Mar 14Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Jan 25Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Aug 26Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 1 experienced director. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Jul 29Second quarter 2021 earnings releasedThe company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: €104.1m (up 4.4% from 2Q 2020). Net income: €25.7m (up 3.9% from 2Q 2020). Profit margin: 25% (in line with 2Q 2020). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Board Change • Jul 29Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 1 experienced director. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • May 04First quarter 2021 earnings releasedThe company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: €104.9m (down 14% from 1Q 2020). Net income: €21.5m (up 3.1% from 1Q 2020). Profit margin: 21% (up from 17% in 1Q 2020). The increase in margin was driven by lower expenses.
Upcoming Dividend • Dec 09Upcoming Dividend of €0.14 Per ShareWill be paid on the 23rd of December to those who are registered shareholders by the 16th of December. The trailing yield of 0.7% is below the top quartile of British dividend payers (4.8%), and is lower than industry peers (3.7%).
Is New 90 Day High Low • Dec 03New 90-day high: €3.83The company is up 17% from its price of €3.29 on 04 September 2020. The British market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €3.50 per share.